HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Irizarry, M. C. Articles by Bottiglieri, T. Search for Related Content PubMed PubMed Citation Articles by Irizarry, M. C. Articles by Bottiglieri, T. Related Collections All Cognitive Disorders/Dementia Alzheimer's disease

Association of homocysteine with plasma amyloid ß protein in aging and neurodegenerative disease

From the Massachusetts Alzheimer Disease Research Center (Drs. Irizarry, Gurol, Raju, Locascio, Tennis, Hyman, Growdon, and Greenberg), Massachusetts General Hospital, Boston, MA; Department of Neurology (Dr. Diaz-Arrastia), University of Texas Southwestern Medical Center, Dallas, TX; Baylor Institute of Metabolic Disease (Dr.Bottiglieri), Dallas, TX.

Address correspondence and reprint requests to Michael C. Irizarry, MD, Alzheimer’s Disease Research Unit, Centers for Aging, Genetics, and Neurodegeneration, Massachusetts General Hospital–East, Building 114, Room 2010, 114 16th Street, Charlestown, MA 02129; e-mail: mirizarry{at}partners.org

Background: Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease and is reported to be an independent risk factor for Alzheimer disease (AD) and cognitive decline. tHcy may potentiate neurotoxic and vasculopathic processes, including amyloid ß protein (Aß) metabolism, implicated in neurodegenerative diseases.

Objective: To examine the relationship of plasma total tHcy levels with clinical, demographic, biochemical, and genetic factors in aging, mild cognitive impairment (MCI), AD, cerebral amyloid angiopathy (CAA), and Parkinson disease (PD).

Methods: Plasma tHcy, folate, vitamin B₁₂, creatinine, and Aß levels were assessed in individuals evaluated in the Memory, Stroke, and Movement Disorders Units of Massachusetts General Hospital with diagnoses of AD (n = 145), MCI (n = 47), PD (n = 93), CAA (67), hypertensive intracerebral hemorrhage (hICH) (n = 25), and no dementia (n = 88).

Results: The tHcy levels did not differ across AD, MCI, CAA, hICH, and nondemented control subjects but were increased in the PD group (p < 0.01). The elevated levels within the PD group were due to high tHcy in individuals taking levodopa (p < 0.0001). Increasing tHcy was associated with worse cognition in the PD cases, but not the other diagnostic groups. tHcy levels positively correlated with plasma Aß levels even after adjustments for age and creatinine (p < 0.0001).

Conclusions: Mean tHcy levels increased with age but did not discriminate diagnostic groups aside from significant elevation in patients with PD taking levodopa. The positive association between tHcy and plasma Aß levels raises the possibility that these circulating factors could interact to affect AD risk and cognition in PD.

Supported by NIH 1T32NS048005-01, AG17861, AG05134 (Massachusetts AD Research Center), AFAR Beeson Award (MCI), and the Lawrence J. and Anne Cable Rubenstein Foundation.

Disclosure: The authors report no conflicts of interest.

Received May 3, 2005. Accepted in final form July 29, 2005.

This article has been cited by other articles:

				P. S. Aisen, L. S. Schneider, M. Sano, R. Diaz-Arrastia, C. H. van Dyck, M. F. Weiner, T. Bottiglieri, S. Jin, K. T. Stokes, R. G. Thomas, et al. High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Controlled Trial JAMA, October 15, 2008; 300(15): 1774 - 1783. [Abstract] [Full Text] [PDF]

				J. Gunstad, M. B. Spitznagel, E. Glickman, T. Alexander, J. Juvancic-Heltzel, K. Walter, and L. Murray {beta}-Amyloid is Associated with Reduced Cognitive Function in Healthy Older Adults J Neuropsychiatry Clin Neurosci, August 1, 2008; 20(3): 327 - 330. [Abstract] [Full Text] [PDF]

				G. Kronenberg, C. Harms, R. W. Sobol, F. Cardozo-Pelaez, H. Linhart, B. Winter, M. Balkaya, K. Gertz, S. B. Gay, D. Cox, et al. Folate Deficiency Induces Neurodegeneration and Brain Dysfunction in Mice Lacking Uracil DNA Glycosylase J. Neurosci., July 9, 2008; 28(28): 7219 - 7230. [Abstract] [Full Text] [PDF]

				J. Kim, M. H. Park, E. Kim, C. Han, S. A. Jo, and I. Jo Plasma Homocysteine Is Associated with the Risk of Mild Cognitive Impairment in an Elderly Korean Population J. Nutr., September 1, 2007; 137(9): 2093 - 2097. [Abstract] [Full Text] [PDF]

				R. Obeid, M. Kasoha, J.-P. Knapp, P. Kostopoulos, G. Becker, K. Fassbender, and W. Herrmann Folate and Methylation Status in Relation to Phosphorylated Tau Protein(181P) and {beta}-Amyloid(1-42) in Cerebrospinal Fluid Clin. Chem., June 1, 2007; 53(6): 1129 - 1136. [Abstract] [Full Text] [PDF]

				E. Sontag, V. Nunbhakdi-Craig, J.-M. Sontag, R. Diaz-Arrastia, E. Ogris, S. Dayal, S. R. Lentz, E. Arning, and T. Bottiglieri Protein Phosphatase 2A Methyltransferase Links Homocysteine Metabolism with Tau and Amyloid Precursor Protein Regulation J. Neurosci., March 14, 2007; 27(11): 2751 - 2759. [Abstract] [Full Text] [PDF]

				M. E. Gurol, M. C. Irizarry, E. E. Smith, S. Raju, R. Diaz-Arrastia, T. Bottiglieri, J. Rosand, J. H. Growdon, and S. M. Greenberg Plasma {beta}-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy Neurology, January 10, 2006; 66(1): 23 - 29. [Abstract] [Full Text] [PDF]